<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870038</url>
  </required_header>
  <id_info>
    <org_study_id>Bernard1</org_study_id>
    <nct_id>NCT00870038</nct_id>
  </id_info>
  <brief_title>To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study</brief_title>
  <acronym>EREMUS</acronym>
  <official_title>Early Re-Endothelialization Might Not be the Unique Solution to Prevent Restenosis. The EREMUS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale della Misericordia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale della Misericordia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators sought to discover which one of the following strategies is the safest for
      patients undergoing percutaneous coronary intervention: paclitaxel-coated balloon+Genous
      stent; Genous stent; drug eluting stent (paclitaxel).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late luminal loss between the three groups at 6 months angiographic follow up.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of stent struts covered by endothelium at optical coherence tomography, during 6 months angiographic follow up.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic restenosis (6 months angiographic follow up).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net adverse clinical events at 6 months (death, myocardial infarction, target lesion revascularization, bleedings as from Acuity scale).</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel eluting balloon (Elutax) + Genous stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uncoated balloon + Genous stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug eluting stent (Taxus stent)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent</intervention_name>
    <description>Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Elutax balloon, Aachen Resonance GmbH, Bavaria, Germany;</other_name>
    <other_name>Genous stent, Orbus Neich, Fort Lauderdale, FL.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention: Uncoated balloon + Genous stent</intervention_name>
    <description>Predilatation with uncoated balloon, the stenting with Genous stent.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Genous stent, Orbus Neich, Fort Lauderdale, FL.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention: Drug eluting stent (Taxus stent)</intervention_name>
    <description>Predilatation with uncoated balloon, the placement of a Taxus stent.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Taxus stent, Boston Scientific, Natick, MA.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable or unstable angina pectoris suitable to PCI of at least one coronary vessel

          -  Age &gt;18 years

        Exclusion Criteria:

          -  Recent (&lt;72 hours) acute myocardial infarction

          -  Creatinine clearance &lt;40 ml/min

          -  Allergy or hypersensitivity to at least two between: aspirin, clopidogrel, heparin,
             bivalirudin, paclitaxel, contrast media

          -  Life expectancy &lt;1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernardo Cortese, MD, FESC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Maggiore Policlinico, Milano, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bernardo Cortese, MD</last_name>
    <phone>+39 02 55033507</phone>
    <email>bcortese@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ugo Limbruno, MD, PhD</last_name>
    <email>bcortese@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>U.O. Emodinamica, Ospedale della Misericordia</name>
      <address>
        <city>Grosseto</city>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bernardo Cortese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, López-Minguez JR, Angel J, Augé JM, Gómez-Recio M, Morís C, Seabra-Gomes R, Perez-Vizcayno MJ, Macaya C; Restenosis Intra-stent: Balloon Angioplasty Versus Elective Stenting (RIBS) Investigators. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol. 2003 Sep 3;42(5):796-805.</citation>
    <PMID>12957423</PMID>
  </results_reference>
  <results_reference>
    <citation>Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Jüni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007 Sep 15;370(9591):937-48. Review.</citation>
    <PMID>17869634</PMID>
  </results_reference>
  <results_reference>
    <citation>Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G, van der Giessen WJ, Regar E, de Feyter PJ, Davis HR, Rowland S, Kutryk MJ. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol. 2005 May 17;45(10):1574-9.</citation>
    <PMID>15893169</PMID>
  </results_reference>
  <results_reference>
    <citation>Co M, Tay E, Lee CH, Poh KK, Low A, Lim J, Lim IH, Lim YT, Tan HC. Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up. Am Heart J. 2008 Jan;155(1):128-32. Epub 2007 Nov 26.</citation>
    <PMID>18082503</PMID>
  </results_reference>
  <results_reference>
    <citation>Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW; Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007 Mar 17;369(9565):907-19.</citation>
    <PMID>17368152</PMID>
  </results_reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <last_update_submitted>July 21, 2010</last_update_submitted>
  <last_update_submitted_qc>July 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bernardo Cortese</name_title>
    <organization>Ospedale della Misericordia</organization>
  </responsible_party>
  <keyword>PCI</keyword>
  <keyword>stent</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>reendothelialization</keyword>
  <keyword>restenosis</keyword>
  <keyword>Percutaneous Coronary Angioplasty</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

